logo

Allena Pharmaceuticals, Inc. (ALNA)



Trade ALNA now with
  Date
  Headline
11/7/2018 8:08:52 AM Allena Pharmaceuticals Q3 Net Loss $9.5 Mln Or $0.46/Shr Vs Net Loss $4.7 Mln Or $3.49/Shr Last Year
10/22/2018 8:12:42 AM Allena Announces Preclinical Proof-of-concept Data For ALLN-346
8/7/2018 8:10:00 AM Allena Pharma Q2 Net Loss $8.6 Mln Or $0.42/Shr Vs Loss $4.6 Mln Or $3.46/Shr Last Year
7/24/2018 9:31:04 AM Wedbush Reiterates Allena Pharmaceuticals, Inc. (ALNA) At Outperform With $38 Price Target
7/23/2018 8:08:04 AM Allena Pharmaceuticals Announces First Patients Treated In Phase 2 Basket Study Of ALLN-177
6/20/2018 7:13:54 AM Wedbush Reiterates Allena Pharmaceuticals, Inc. (ALNA) At Outperform With $38 Price Target
6/19/2018 8:22:59 AM Allena Completes Animal Proof-of-Concept Study For ALLN-346
6/11/2018 8:07:09 AM Allena Pharmaceuticals Appoints Andrew Hack To Board Of Directors
5/8/2018 8:11:08 AM Allena Q1 Net Loss $7.9 Mln Or $0.38/Shr
3/28/2018 8:46:00 AM Wedbush Is Lowering Allena Pharmaceuticals, Inc. (ALNA) FY18 Estimate To -1.50 From -1.48
3/28/2018 8:45:46 AM Wedbush Is Cutting Allena Pharmaceuticals, Inc. (ALNA) Q2 18 Estimate To -0.38 From -0.37
3/28/2018 8:45:36 AM Wedbush Is Cutting Allena Pharmaceuticals, Inc. (ALNA) Q1 18 Estimate To -0.38 From -0.37
3/28/2018 8:45:02 AM Wedbush Reiterates Allena Pharmaceuticals, Inc. (ALNA) At Outperform With $37 Price Target
3/27/2018 8:10:24 AM Allena Pharma Q4 Net Loss $6.68 Mln Or $0.48/Shr Vs Loss $6.22 Mln Or $4.65/Shr Last Year
3/6/2018 8:11:57 AM Allena Begins First Phase 3 Trial For ALLN-177 In Patients With Enteric Hyperoxaluria
12/18/2017 6:21:31 AM Wedbush Is Lowering Allena Pharmaceuticals, Inc. (ALNA) 2018 Estimate To -1.48 From -1.42